Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “SION”

1,496 pharma patents match "SION" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,496
Index total 30,257
Page 15 / 63

Quick answer

This filtered view shows 1,496 pharmaceutical patents matching "SION" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,496 results for “SION” · 30,257 patents in full index Clear search

  1. US 11230712

    Compounds and methods for reducing SNCA expression

    Ionis Pharmaceuticals, Inc. · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  2. US 11225664

    Modulation of angiopoietin-like 3 expression

    Ionis Pharmaceuticals, Inc. · Granted Jan 18, 2022 · Expires Jan 13, 2042

    granted

  3. US 11225641

    Probiotic Bifidobacterium strain

    PrecisionBiotics Group Limited · Granted Jan 18, 2022 · Expires Jan 13, 2042

    granted

  4. US 11214803

    Modulators of YAP1 expression

    Ionis Pharmaceuticals, Inc. · Granted Jan 4, 2022 · Expires Dec 30, 2041

    granted

  5. US 11214801

    RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)

    Arrowhead Pharmaceuticals, Inc. · Granted Jan 4, 2022 · Expires Dec 30, 2041

    granted

  6. US 11214802

    RNAi agents for inhibiting expression of alpha-ENaC and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Jan 4, 2022 · Expires Dec 30, 2041

    granted

  7. US 11208650

    Modulators of IRF5 expression

    Ionis Pharmaceuticals, Inc. · Granted Dec 28, 2021 · Expires Dec 23, 2041

    granted

  8. US 11208662

    RNAi inhibition of alpha-ENaC expression

    Arrowhead Pharmaceuticals, Inc. · Granted Dec 28, 2021 · Expires Dec 23, 2041

    granted

  9. US 11197837

    Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse

    Acurx Pharmaceuticals, Inc. · Granted Dec 14, 2021 · Expires Dec 9, 2041

    granted

  10. US 11198876

    Compositions and methods for inhibiting expression of TMPRSS6 gene

    Alnylam Pharmaceuticals, Inc. · Granted Dec 14, 2021 · Expires Dec 9, 2041

    granted

  11. US 11192903

    Zirconium-89 oxine complex as a cell labeling agent for positron emission tomography

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 7, 2021 · Expires Dec 2, 2041

    granted

  12. US 11193128

    Compositions for modulating expression of C9ORF72 antisense transcript

    Ionis Pharmaceuticals, Inc. · Granted Dec 7, 2021 · Expires Dec 2, 2041

    granted

  13. US 11191761

    SOMCL-9112 solid dispersion and preparation method thereof and SOMCL-9112 solid preparation containing SOMCL-9112 solid dispersion

    Shanghai Acebright Pharmaceuticals Group Co., Ltd. · Granted Dec 7, 2021 · Expires Dec 2, 2041

    granted

  14. US 11191935

    Implant delivery system with hydration promotor capability

    Nano Precision Medical, Inc. · Granted Dec 7, 2021 · Expires Dec 2, 2041

    granted

  15. US 11186626

    Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop

    INTEGRATED BIOTHERAPEUTICS, INC. · Granted Nov 30, 2021 · Expires Nov 25, 2041

    granted

  16. US 11186822

    Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)

    Precision BioSciences, Inc. · Granted Nov 30, 2021 · Expires Nov 25, 2041

    granted

  17. US 11180765

    Regulated expression of antigen and/or regulated attenuation to enhance vaccine immunogenicity and/or safety

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Nov 23, 2021 · Expires Nov 18, 2041

    granted

  18. US 11180562

    Method of treating or delaying progression of an epidermal growth factor receptor (EGFR)-related disorder by administering activatable EGFR-binding antibodies

    CytomX Therapeutics, Inc. · Granted Nov 23, 2021 · Expires Nov 18, 2041

    granted

  19. CA 3172874

    COMPOSITIONS DE POLYPEPTIDES DE FUSION D'IL-2 ET LEURS PROCEDES DE FABRICATION ET D'UTILISATION

    ALKERMES PHARMA IRELAND LTD [IE] · Granted Nov 18, 2021 · Expires Nov 13, 2041

    granted

  20. CA 3172871

    COMPOSITIONS DE POLYPEPTIDES DE FUSION D'IL-2 ET LEURS PROCEDES DE FABRICATION ET D'UTILISATION

    ALKERMES PHARMA IRELAND LTD [IE] · Granted Nov 18, 2021 · Expires Nov 13, 2041

    granted

  21. US 11173118

    Emulsion formulations of an NK-1 receptor antagonist and uses thereof

    Heron Therapeutics, Inc. · Granted Nov 16, 2021 · Expires Nov 11, 2041

    granted

  22. US 11174292

    Substitutions-modified prefusion RSV F proteins and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 16, 2021 · Expires Nov 11, 2041

    granted

  23. US 11162096

    Methods for modulating expression of C9ORF72 antisense transcript

    The Regents of the University of California · Granted Nov 2, 2021 · Expires Oct 28, 2041

    granted

  24. US 11155815

    Compositions and methods for modulating Tau expression

    Ionis Pharmaceuticals, Inc. · Granted Oct 26, 2021 · Expires Oct 21, 2041

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.